• Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Applications of proteomics: Toxicology

May 2, 2023
Gracie Murphy
LinkedIn

While toxicology has improved human health and safety, comprehensive proteomic analyses could reveal the molecular innerworkings associated with toxicity and off-target drug effects – improving toxicologists’ ability to predict adverse outcomes in pre-clinical models and beyond.

 

Graphic symbolically depicting how proteomics can be used in toxicology. The graphic reads, "Comprehensive proteomic analysis could provide insights into the molecular mechanisms associated with toxicity." It depicts the results of proteomics measurements taken before exposure to various toxins and after exposure to toxins. The levels of various proteins across the proteome change after exposure to toxins.

A role for comprehensive proteomics in toxicology

If you have ever drunk water from the tap, taken a dose of medication, or breathed in fresh air without accidentally poisoning yourself – you can thank toxicology. Researchers in this important field study the detection and effects of possible toxins. Toxin is a broad term and can refer to anything from harmful chemical exposures, to substances in prescription medicine. Work in this field provides us with the ability to detect harmful substances, determine the dose at which they become dangerous, and ascertain whether a substance has detrimental effects in the first place. However, current toxicology techniques are far from perfect, particularly in the area of pharmaceutical development, often missing unwanted side effects of drugs. Having new technologies that can better analyze potential toxins and their effects will go a long way toward improving human health and safety.

 

In this post, we will explore the potentially powerful role of comprehensive proteomic analysis in identifying biomarkers of toxicity and assessing off-target effects of drugs at the molecular level.

 

How do you know if something is poisoning you?

Despite what we see in the movies, ingesting toxic substances does not always lead to instantaneous foaming at the mouth or a dramatic collapse into a plate of (apparently poisoned) food. Many of the toxins we encounter on a daily basis have much more subtle impacts that accumulate over time – DNA damage, buildup of harmful agents, or worsening of preexisting conditions. A major focus of toxicology is discovering the damage and agents responsible before subtle impacts turn into chronic illnesses.

 

Current toxicology methods evaluate effects of substances in vitro or in animal models to uncover endpoints that are adversely impacted, such as cell death or the occurrence of developmental defects. In vitro experiments utilize cells, tissues, or organs to study toxin effects in a controlled environment – evaluating cytotoxicity, cell proliferation, membrane integrity, and other localized outcomes. The simplified nature of in vitro models often limits accurate representation of toxicity response.

 

In contrast, animal models provide a means for evaluating toxin distribution, effect on physiology, and biochemical interactions across several organs in a live organism. Unfortunately, the significant biological differences – such as cell distribution or blood pH – between test animals and humans reduce the predictability of these models. These techniques draw an incomplete picture and fail to reveal impacts on more nuanced molecular and biochemical pathways, especially those involved in homeostatic processes.

 

The vast potential of proteomics in toxicology

Transcriptomics is often used to assess toxicological response in these experiments, but mRNA transcript levels only partially correlate to protein levels due to a variety of biological processes. More accurate assessments of the ways toxins alter proteins associated with various cellular functions would provide informative measures for toxicity. For example, post translational modifications of proteins related to cell growth, division, stress, or repair– like p53 or hypoxia inducible factor – might reveal adverse effects that are not obvious from the mRNA alone.

 

In a 2014 review covering proteomics for systems toxicology, the authors highlighted the need for comprehensive insights into molecular toxicological mechanisms in order to improve toxicity predictions. The ability to measure changes at the molecular level within cells, tissues, and entire animals in response to exposure would allow more specific identification of relevant pathways in model systems. Understanding which molecular players are involved, and what modifications initiate their active state during a toxicity response would help to narrow in on these toxicological mechanisms.

 

The Nautilus Proteome Analysis Platform may be able to fill this technological gap. It is designed to rigorously probe protein abundance and modifications at varying levels of biological complexity. This detailed proteomic analysis could enhance the predictive ability of animal and in vitro toxicity models through a sensitive assessment of subtle changes in homeostatic biomolecules prior to cell death. It could also reveal the molecular basis behind toxin interactions in specific organs.

 

Toxicology (and proteomics) in drug discovery and safety

A related arm of toxicology focuses on the potential harm that can arise from pharmaceuticals, often known as off-target effects. We are all familiar with the long lists of side effects recited at the end of pharmaceutical commercials. These adverse side effects often arise from unintended, and unwanted, interactions with non-target molecules, pathways, or cell types. Sometimes, off-target effects are sufficient to knock drug candidates out of clinical trials, but the adverse effects of many drugs are not apparent until they’ve already hit the market because our current methods of measuring toxicity are not sufficient. Both human health and the costly drug development process would greatly benefit from a way to predict off-target effects in pre-clinical studies.

 

Proteomics has previously been used to expose off-target effects. An example of this was the use of mass spectrometry to uncover the molecular link between liver toxicity and Troglitazone, a since withdrawn type-II diabetes medication. Following removal from the market, researchers utilized proteomics to track Troglitazone associated mitochondrial protein changes in rodents, revealing deterioration of relevant proteins and dysfunction of transport systems leading to liver injury. Troglitazone and its associated risk of liver injury in some patients highlight the need for a robust method for detecting early signs of drug toxicity.

 

The Nautilus Proteome Analysis Platform could provide the expanded proteome coverage needed to reveal off-target interactions in the early stages of drug development. Rather than only investigating proteins of interest or those that are biologically linked to drug targets, robust proteome analyses can show the whole picture – they can clue researchers on to seemingly unrelated molecular modulations that may translate to nasty side effects down the line. Thus, with a comprehensive proteomic analysis platform designed to reveal these issues, researchers can mitigate them before a drug is released or provide physicians with the information needed to avoid or treat the toxic side effects. This may lead to safer drugs for all.

Browse by topic

  • Nautilus in the News
  • Events
  • Research and Collaborations
  • Applications of Proteomics
  • Nautilus and our Platform
  • Proteomics
  • Life at Nautilus
  • Industry Interviews
SUBSCRIBE
Back To Blog

Nautilus Biotechnology

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

 

     

+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

We use cookies in order to continually improve your experience on our website. By clicking “Accept cookies” or clicking on any content on our site, you are consenting to our use of cookies as described in our Privacy Policy. You can opt-out if you wish. Accept Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT